We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million total ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...

Illumina and Regeneron are taking stakes in the health data company Truveta to help fund research that may dwarf the efforts ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

Telix Pharmaceuticals’ expansion phase shows no sign of running out yet, with the Australian radiopharma company paying $45 ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Investors clearly appreciate the song that Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

As it works to build a 775-acre research campus in the Florida heat, the Moffitt Cancer Center is looking to cool things down ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...